Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)
Death receptor 3 (DR3) and its corresponding ligand, tumor necrosis factor-like ligand 1A (TL1A), belong to the tumor necrosis factor superfamily. Signaling via this receptor-ligand pair results in pro-inflammatory and anti-inflammatory effects. Effector lymphocytes can be activated to exert pro-inf...
Gespeichert in:
| Veröffentlicht in: | Experimental and therapeutic medicine 2021-07, Vol.22 (1), p.693-693, Article 693 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 693 |
|---|---|
| container_issue | 1 |
| container_start_page | 693 |
| container_title | Experimental and therapeutic medicine |
| container_volume | 22 |
| creator | Yu, Yunhong Jiang, Peng Sun, Pan Su, Na Lin, Fangzhao |
| description | Death receptor 3 (DR3) and its corresponding ligand, tumor necrosis factor-like ligand 1A (TL1A), belong to the tumor necrosis factor superfamily. Signaling via this receptor-ligand pair results in pro-inflammatory and anti-inflammatory effects. Effector lymphocytes can be activated to exert pro-inflammatory activity by triggering the DR3/TL1A pathway. By contrast, DR3/TL1A signaling also induces expansion of the suppressive function of regulatory T cells, which serve an important role in exerting anti-inflammatory functions and maintaining immune homeostasis. Preclinical evidence indicates that neutralizing and agonistic antibodies, as well as ligand-based approaches targeting the DR3/TL1A pathway, may be used to treat diseases, including inflammatory and immune-mediated diseases. Accumulating evidence has suggested that modulating the DR3/TL1A pathway is a promising therapeutic approach for patients with these diseases. This review discusses preclinical models to gauge the progress of therapeutic strategies for diseases involving the DR3/TL1A pathway to aid in drug development. |
| doi_str_mv | 10.3892/etm.2021.10125 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8111866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669991171</galeid><sourcerecordid>A669991171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-96d1794320cfc1382816d74cecf9710bbbeb971c6a9135b593ae1230ddd075b13</originalsourceid><addsrcrecordid>eNptUk1r3DAQNaWlCWmuPRZDL-lhNxrJkqVLYUmatrBQCOlZyNI4qyBbrmUn7L-v3GzTDyIdNKN58-aDVxRvgayZVPQcp25NCYU1EKD8RXEMtaKr7PCXB5soCUfFaUp3JB8uQEr-ujhiTEkhuTwucNObsE8-lbEtpx2OZsB58rYc4oT95E1YAsOINvje2-x20WFIZWMSujL25eU1O7_ZwqYczLR7MPsFMAcz-Rw7u8Z7jw8f3hSvWhMSnh7ek-L71aebiy-r7bfPXy8225WtgE8rJVzuumKU2NYCk1SCcHVl0baqBtI0DTbZsMIoYLzhihkEyohzjtS8AXZSfHzkHeamQ2fzBKMJehh9Z8a9jsbrfyO93-nbeK8lAEghMsHZgWCMP2ZMk-58shiC6THOSVOee6plXdMMff8f9C7OY97mgmK04rxS7A_q1gTUvm9jrmsXUr0RQikFUC99r59B5euw8zb22Pr8_1yCHWNKI7ZPMwLRizZ01oZetKF_aSMnvPt7M0_w30pgPwF6cLNn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2532455493</pqid></control><display><type>article</type><title>Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)</title><source>PubMed Central</source><creator>Yu, Yunhong ; Jiang, Peng ; Sun, Pan ; Su, Na ; Lin, Fangzhao</creator><creatorcontrib>Yu, Yunhong ; Jiang, Peng ; Sun, Pan ; Su, Na ; Lin, Fangzhao</creatorcontrib><description>Death receptor 3 (DR3) and its corresponding ligand, tumor necrosis factor-like ligand 1A (TL1A), belong to the tumor necrosis factor superfamily. Signaling via this receptor-ligand pair results in pro-inflammatory and anti-inflammatory effects. Effector lymphocytes can be activated to exert pro-inflammatory activity by triggering the DR3/TL1A pathway. By contrast, DR3/TL1A signaling also induces expansion of the suppressive function of regulatory T cells, which serve an important role in exerting anti-inflammatory functions and maintaining immune homeostasis. Preclinical evidence indicates that neutralizing and agonistic antibodies, as well as ligand-based approaches targeting the DR3/TL1A pathway, may be used to treat diseases, including inflammatory and immune-mediated diseases. Accumulating evidence has suggested that modulating the DR3/TL1A pathway is a promising therapeutic approach for patients with these diseases. This review discusses preclinical models to gauge the progress of therapeutic strategies for diseases involving the DR3/TL1A pathway to aid in drug development.</description><identifier>ISSN: 1792-0981</identifier><identifier>EISSN: 1792-1015</identifier><identifier>DOI: 10.3892/etm.2021.10125</identifier><identifier>PMID: 33986858</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Care and treatment ; Cell receptors ; Cellular signal transduction ; Drug development ; Drug discovery ; Genetic aspects ; Health aspects ; Immunologic diseases ; Inflammatory bowel disease ; Kinases ; Lymphocytes ; Pharmacology, Experimental ; Review ; Tumor necrosis factor-TNF</subject><ispartof>Experimental and therapeutic medicine, 2021-07, Vol.22 (1), p.693-693, Article 693</ispartof><rights>Copyright: © Yu et al.</rights><rights>COPYRIGHT 2021 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2021</rights><rights>Copyright: © Yu et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-96d1794320cfc1382816d74cecf9710bbbeb971c6a9135b593ae1230ddd075b13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111866/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111866/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33986858$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yu, Yunhong</creatorcontrib><creatorcontrib>Jiang, Peng</creatorcontrib><creatorcontrib>Sun, Pan</creatorcontrib><creatorcontrib>Su, Na</creatorcontrib><creatorcontrib>Lin, Fangzhao</creatorcontrib><title>Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)</title><title>Experimental and therapeutic medicine</title><addtitle>Exp Ther Med</addtitle><description>Death receptor 3 (DR3) and its corresponding ligand, tumor necrosis factor-like ligand 1A (TL1A), belong to the tumor necrosis factor superfamily. Signaling via this receptor-ligand pair results in pro-inflammatory and anti-inflammatory effects. Effector lymphocytes can be activated to exert pro-inflammatory activity by triggering the DR3/TL1A pathway. By contrast, DR3/TL1A signaling also induces expansion of the suppressive function of regulatory T cells, which serve an important role in exerting anti-inflammatory functions and maintaining immune homeostasis. Preclinical evidence indicates that neutralizing and agonistic antibodies, as well as ligand-based approaches targeting the DR3/TL1A pathway, may be used to treat diseases, including inflammatory and immune-mediated diseases. Accumulating evidence has suggested that modulating the DR3/TL1A pathway is a promising therapeutic approach for patients with these diseases. This review discusses preclinical models to gauge the progress of therapeutic strategies for diseases involving the DR3/TL1A pathway to aid in drug development.</description><subject>Care and treatment</subject><subject>Cell receptors</subject><subject>Cellular signal transduction</subject><subject>Drug development</subject><subject>Drug discovery</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Immunologic diseases</subject><subject>Inflammatory bowel disease</subject><subject>Kinases</subject><subject>Lymphocytes</subject><subject>Pharmacology, Experimental</subject><subject>Review</subject><subject>Tumor necrosis factor-TNF</subject><issn>1792-0981</issn><issn>1792-1015</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptUk1r3DAQNaWlCWmuPRZDL-lhNxrJkqVLYUmatrBQCOlZyNI4qyBbrmUn7L-v3GzTDyIdNKN58-aDVxRvgayZVPQcp25NCYU1EKD8RXEMtaKr7PCXB5soCUfFaUp3JB8uQEr-ujhiTEkhuTwucNObsE8-lbEtpx2OZsB58rYc4oT95E1YAsOINvje2-x20WFIZWMSujL25eU1O7_ZwqYczLR7MPsFMAcz-Rw7u8Z7jw8f3hSvWhMSnh7ek-L71aebiy-r7bfPXy8225WtgE8rJVzuumKU2NYCk1SCcHVl0baqBtI0DTbZsMIoYLzhihkEyohzjtS8AXZSfHzkHeamQ2fzBKMJehh9Z8a9jsbrfyO93-nbeK8lAEghMsHZgWCMP2ZMk-58shiC6THOSVOee6plXdMMff8f9C7OY97mgmK04rxS7A_q1gTUvm9jrmsXUr0RQikFUC99r59B5euw8zb22Pr8_1yCHWNKI7ZPMwLRizZ01oZetKF_aSMnvPt7M0_w30pgPwF6cLNn</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Yu, Yunhong</creator><creator>Jiang, Peng</creator><creator>Sun, Pan</creator><creator>Su, Na</creator><creator>Lin, Fangzhao</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210701</creationdate><title>Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)</title><author>Yu, Yunhong ; Jiang, Peng ; Sun, Pan ; Su, Na ; Lin, Fangzhao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-96d1794320cfc1382816d74cecf9710bbbeb971c6a9135b593ae1230ddd075b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>Cell receptors</topic><topic>Cellular signal transduction</topic><topic>Drug development</topic><topic>Drug discovery</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Immunologic diseases</topic><topic>Inflammatory bowel disease</topic><topic>Kinases</topic><topic>Lymphocytes</topic><topic>Pharmacology, Experimental</topic><topic>Review</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>online_resources</toplevel><creatorcontrib>Yu, Yunhong</creatorcontrib><creatorcontrib>Jiang, Peng</creatorcontrib><creatorcontrib>Sun, Pan</creatorcontrib><creatorcontrib>Su, Na</creatorcontrib><creatorcontrib>Lin, Fangzhao</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental and therapeutic medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Yunhong</au><au>Jiang, Peng</au><au>Sun, Pan</au><au>Su, Na</au><au>Lin, Fangzhao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review)</atitle><jtitle>Experimental and therapeutic medicine</jtitle><addtitle>Exp Ther Med</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>22</volume><issue>1</issue><spage>693</spage><epage>693</epage><pages>693-693</pages><artnum>693</artnum><issn>1792-0981</issn><eissn>1792-1015</eissn><abstract>Death receptor 3 (DR3) and its corresponding ligand, tumor necrosis factor-like ligand 1A (TL1A), belong to the tumor necrosis factor superfamily. Signaling via this receptor-ligand pair results in pro-inflammatory and anti-inflammatory effects. Effector lymphocytes can be activated to exert pro-inflammatory activity by triggering the DR3/TL1A pathway. By contrast, DR3/TL1A signaling also induces expansion of the suppressive function of regulatory T cells, which serve an important role in exerting anti-inflammatory functions and maintaining immune homeostasis. Preclinical evidence indicates that neutralizing and agonistic antibodies, as well as ligand-based approaches targeting the DR3/TL1A pathway, may be used to treat diseases, including inflammatory and immune-mediated diseases. Accumulating evidence has suggested that modulating the DR3/TL1A pathway is a promising therapeutic approach for patients with these diseases. This review discusses preclinical models to gauge the progress of therapeutic strategies for diseases involving the DR3/TL1A pathway to aid in drug development.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>33986858</pmid><doi>10.3892/etm.2021.10125</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-0981 |
| ispartof | Experimental and therapeutic medicine, 2021-07, Vol.22 (1), p.693-693, Article 693 |
| issn | 1792-0981 1792-1015 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8111866 |
| source | PubMed Central |
| subjects | Care and treatment Cell receptors Cellular signal transduction Drug development Drug discovery Genetic aspects Health aspects Immunologic diseases Inflammatory bowel disease Kinases Lymphocytes Pharmacology, Experimental Review Tumor necrosis factor-TNF |
| title | Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T13%3A35%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20of%20therapeutic%20potential%20of%20preclinical%20models%20based%20on%20DR3/TL1A%20pathway%20modulation%20(Review)&rft.jtitle=Experimental%20and%20therapeutic%20medicine&rft.au=Yu,%20Yunhong&rft.date=2021-07-01&rft.volume=22&rft.issue=1&rft.spage=693&rft.epage=693&rft.pages=693-693&rft.artnum=693&rft.issn=1792-0981&rft.eissn=1792-1015&rft_id=info:doi/10.3892/etm.2021.10125&rft_dat=%3Cgale_pubme%3EA669991171%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2532455493&rft_id=info:pmid/33986858&rft_galeid=A669991171&rfr_iscdi=true |